[go: up one dir, main page]

MX2023011829A - Derivados de uracilo como inhibidores de trpa1. - Google Patents

Derivados de uracilo como inhibidores de trpa1.

Info

Publication number
MX2023011829A
MX2023011829A MX2023011829A MX2023011829A MX2023011829A MX 2023011829 A MX2023011829 A MX 2023011829A MX 2023011829 A MX2023011829 A MX 2023011829A MX 2023011829 A MX2023011829 A MX 2023011829A MX 2023011829 A MX2023011829 A MX 2023011829A
Authority
MX
Mexico
Prior art keywords
uracil derivatives
trpa1
trpa1 inhibitors
inhibitors
derivatives
Prior art date
Application number
MX2023011829A
Other languages
English (en)
Inventor
Jens Willwacher
Martin Thomas Fleck
Florian Paul Christian Binder
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2023011829A publication Critical patent/MX2023011829A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente descripción proporciona algunos derivados de uracilo que son inhibidores del potencial de receptor transitorio anquirina 1 (TRPA1), y son por lo tanto útiles para el tratamiento de enfermedades que se pueden tratar mediante inhibición de TRPA1. Asimismo, se proporcionan composiciones farmacéuticas que los contienen, y procesos para la preparación de dichos compuestos. (ver Fórmula).
MX2023011829A 2021-04-14 2022-04-13 Derivados de uracilo como inhibidores de trpa1. MX2023011829A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21168433 2021-04-14
PCT/EP2022/059816 WO2022219013A1 (en) 2021-04-14 2022-04-13 Uracil derivatives as trpa1 inhibitors

Publications (1)

Publication Number Publication Date
MX2023011829A true MX2023011829A (es) 2023-10-13

Family

ID=75539076

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023011829A MX2023011829A (es) 2021-04-14 2022-04-13 Derivados de uracilo como inhibidores de trpa1.

Country Status (13)

Country Link
US (1) US11858921B2 (es)
EP (1) EP4323355A1 (es)
JP (1) JP7617306B2 (es)
KR (1) KR20230170934A (es)
CN (1) CN117083269A (es)
AU (1) AU2022259537A1 (es)
BR (1) BR112023015425A2 (es)
CA (1) CA3209982A1 (es)
CL (1) CL2023002633A1 (es)
IL (1) IL306065A (es)
MX (1) MX2023011829A (es)
TW (1) TW202309015A (es)
WO (1) WO2022219013A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11884652B2 (en) 2020-06-29 2024-01-30 Boehringer Ingelheim International Gmbh Tetrazole derivatives as TRPA1 inhibitors
EP4323364A1 (en) 2021-04-14 2024-02-21 Boehringer Ingelheim International GmbH Imidazo[4,5-d]pyridazinonyl derivatives as trpa1 inhibitors
WO2023150592A2 (en) * 2022-02-03 2023-08-10 D.E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361654B2 (en) * 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
JP7171567B2 (ja) 2016-11-28 2022-11-15 エフ．ホフマン－ラ ロシュ アーゲー 一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類
CN114874209B (zh) 2017-03-07 2024-08-06 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
EP4045509A1 (en) 2019-10-15 2022-08-24 Boehringer Ingelheim International GmbH Thienopyrimidones as trpa1 inhibitors
US11884652B2 (en) 2020-06-29 2024-01-30 Boehringer Ingelheim International Gmbh Tetrazole derivatives as TRPA1 inhibitors
PL4323368T3 (pl) 2021-04-14 2025-06-23 Boehringer Ingelheim International Gmbh 3h,4h,5h,6h,7h-pirymido[4,5-b][1,4]oksazyno-4,6-dionowe pochodne jako inhibitory trpa1
JP7565457B2 (ja) 2021-04-14 2024-10-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ＴＲＰＡ１阻害剤としての３Ｈ，４Ｈ－チエノ－［２，３－ｄ］ピリミジン－４－オン誘導体
EP4323364A1 (en) 2021-04-14 2024-02-21 Boehringer Ingelheim International GmbH Imidazo[4,5-d]pyridazinonyl derivatives as trpa1 inhibitors

Also Published As

Publication number Publication date
JP2024512972A (ja) 2024-03-21
IL306065A (en) 2023-11-01
BR112023015425A2 (pt) 2023-11-07
AU2022259537A9 (en) 2024-10-17
AU2022259537A1 (en) 2023-08-17
US20220340552A1 (en) 2022-10-27
CA3209982A1 (en) 2022-10-20
EP4323355A1 (en) 2024-02-21
JP7617306B2 (ja) 2025-01-17
CN117083269A (zh) 2023-11-17
WO2022219013A1 (en) 2022-10-20
CL2023002633A1 (es) 2024-03-15
US11858921B2 (en) 2024-01-02
KR20230170934A (ko) 2023-12-19
TW202309015A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
MX2022013223A (es) [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2.
PH12021550604A1 (en) Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2021012549A (es) Derivados de tetrahidro-1h-ciclopenta[cd]indeno como inhibidores del factor inducible por hipoxia-2(alfa).
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
PH12019500036A1 (en) Heterocyclic compound used as fgfr inhibitor
WO2019226213A3 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
PH12021551304A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
PH12022551623A1 (en) Substituted pyrazolo-pyrimidines and uses thereof
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX2023011828A (es) Derivados de 3h,4h,5h,6h,7h-pirimido[4,5-b][1,4]oxazin-4,6-diona como inhibidores de trpa1.
SA522441965B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2024011755A (es) Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
MX2023011830A (es) Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1.
SA522441973B1 (ar) Trpa1 مشتقات تترازول كمثبطات لـ
MX2023014784A (es) Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos.
SA523440367B1 (ar) مشتقات تترازول كمثبطات لمستقبل عابر أنكيرين قوي 1
PH12021550258A1 (en) Cdk8/19 inhibitors
WO2025043225A3 (en) Dioxopiperidine-indolone-methylene-carbamate compounds as degraders of cyclin-dependent kinase 2